IBT Vaccines, a wholly owned subsidiary of Integrated Biotherapeutics Inc., announces it has received $3.9 million…
Moving from pre-clinical to clinical-stage
IBT CEO Dr. M. Javad Aman will discuss the development of a multi-component toxoid vaccine for S. aureus and the regulatory challenges and opportunities when moving a product from pre-clinical to clinical stage. The live webinar scheduled for Sept. 24, 2020 will feature experts on various aspects of antimicrobial resistance (AMR) who will share their knowledge and opinions the current state of the AMR R&D field.
